Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 2003; 63: 8476-80. (PMID: 14679012) [PubMed]

Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother 2006; 55: 1515-23. (PMID: 16622681) [ PubMed]

Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Bröcker EB, thor Straten P, Rapp UR, Becker JC. Immunogenicity of constitutively active ^V599EBRaf. Cancer Res 2004; 64: 5456-60. (PMID: 15289355) [PubMed]

Anderson BW, Kudelka AP, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JL, Ioannides CG. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 2000; 49: 459-68. (PMID: 11092612) [PubMed]

Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res 2004; 10: 6695-702. (PMID: 15475460) [PubMed]

Azuma T, Makita M, Ninomiya K, Fujita S, Harada M, Yasukawa M. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 2002; 116: 601-3. (PMID: 11849218) [PubMed]

Bar-Haim E, Paz A, Machlenkin A, Hazzan D, Tirosh B, Carmon L, Brenner B, Vadai E, Mor O, Stein A, Lemonnier FA, Tzehoval E, Eisenbach L. MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. Br J Cancer 2004; 91: 398-407. (PMID: 15213716) [PubMed]

Basak S, Birebent B, Purev E, Somasundaram R, Maruyama H, Zaloudik J, Swoboda R, Strittmatter W, Li W, Luckenbach A, Song H, Li J, Sproesser K, Guerry D, Nair S, Furukawa K, Herlyn D. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother 2003; 52: 145-54. (PMID: 12649743) [PubMed]

Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM, Stauss HJ. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002; 100: 3835-7. (PMID: 12411326) [PubMed]

Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-92. (PMID: 8611681) [PubMed]

Bohm CM, Hanski ML, Stefanovic S, Rammensee HG, Stein H, Taylor-Papadimitriou J, Riecken EO, Hanski C. Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. Int J Cancer 1998; 75: 688-93. (PMID: 9495235) [PubMed]

Bredenbeck A, Losch FO, Sharav T, Eichler-Mertens M, Filter M, Givehchi A, Sterry W, Wrede P, Walden P. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy. J Immunol 2005; 174: 6716-24. (PMID: 15905511) [PubMed]

Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC, Speiser DE. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005; 174: 1709-16. (PMID: 15661935) [PubMed]

Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. Exp Hematol 2007; 35: 920-30. (PMID: 17533046) [PubMed]

Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet JG, Choppin J. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997; 27: 2066-72. (PMID: 9295046) [PubMed]

Carmon L, Bobilev-Priel I, Brenner B, Bobilev D, Paz A, Bar-Haim E, Tirosh B, Klein T, Fridkin M, Lemonnier F, Tzehoval E, Eisenbach L. Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice. J Clin Invest 2002; 110: 453-62. (PMID: 12189239) [PubMed]

Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB. P53_110-124-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 2003; 63: 3675-81. (PMID: 12839958) [PubMed]

Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PL, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-93. (PMID: 11698267) [PubMed]

Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol 1998; 114: 166-72. (PMID: 9822272) [PubMed]

Correa I, Plunkett T, Coleman J, Galani E, Windmill E, Burchell JM, Taylor-Papdimitriou J. Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int J Cancer 2005; 115: 760-8. (PMID: 15729696) [PubMed]

Dangles V, Halberstam I, Scardino A, Choppin J, Wertheimer M, Richon S, Quelvennec E, Moirand R, Guillet JG, Kosmatopoulos K, Bellet D, Zeliszewski D. Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes. Cancer Immunol Immunother 2002; 50: 673-81. (PMID: 11862419) [PubMed]

Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci U S A 2004; 101: 10697-702. (PMID: 15252201) [PubMed]

Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995; 155: 4766-74. (PMID: 7594478) [PubMed]

Dong HL, Li ZS, Ye J, Qu P, Huang YY, Wu W, Lu SY, Chen GS, Sui YF. Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. Cancer Biol Ther 2004; 3: 891-8. (PMID: 15326372) [PubMed]

Dong HL, Sui YF, Li ZS, Qu P, Wu W, Ye J, Zhang XM, Lu SY. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro. Cancer Lett 2004; 211: 219-25. (PMID: 15219945) [PubMed]

Dörrschuck A, Schmidt A, Schnürer E, Glückmann M, Albrecht C, Wölfel C, Lennerz V, Lifke A, Di Natale C, Ranieri E, Gesualdo L, Huber C, Karas M, Wölfel T, Herr W. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 2004; 104: 2591-9. (PMID: 15231579) [PubMed]

Elkord E, Williams PE, Kynaston H, Rowbottom AW. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. Int Immunol 2005; 17: 1315-25. (PMID: 16141246) [PubMed]

Faure O, Graff-Dubois S, Bretaudeau L, Derré L, Gross D-A, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Grégoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K. Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer 2004; 108: 863-70. (PMID: 14712489) [PubMed]

Flad T, Mueller L, Dihazi H, Grigorova V, Bogumil R, Beck A, Thedieck C, Mueller GA, Kalbacher H, Mueller CA. T cell epitope definition by differential mass spectrometry: identification of a novel, immunogenic HLA-B8 ligand directly from renal cancer tissue. Proteomics 2006; 6: 364-74. (PMID: 16196104) [PubMed]

Fleischhauer K, Gattinoni L, Dalerba P, Lauvau G, Zanaria E, Dabovic B, van Endert PM, Bordignon C, Traversari C. The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes. Cancer Res 1998; 58: 2969-72. (PMID: 9679956) [PubMed]

Francini G, Scardino A, Kosmatopoulos K, Lemonnier FA, Campoccia G, Sabatino M, Pozzessere D, Petrioli R, Lozzi L, Neri P, Fanetti G, Cusi MG, Correale P. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J Immunol 2002; 169: 4840-9. (PMID: 12391194) [PubMed]

Friedman RS, Bangur CS, Zasloff EJ, Fan L, Wang T, Watanabe Y, Kalos M. Molecular and immunological evaluation of the transcription factor SOX-4 as a lung tumor vaccine antigen. J Immunol 2004a; 172: 3319-27. (PMID: 14978140) [PubMed]

Friedman RS, Spies AG, Kalos M. Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. Eur J Immunol 2004b; 34: 1091-101. (PMID: 15048720) [PubMed]

Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 1999; 80: 169-72. (PMID: 9935194) [PubMed]

Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, Stauss HJ. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-203. (PMID: 10733485) [PubMed]

Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160: 328-33. (PMID: 9551988) [PubMed]

Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Itoh K. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999; 163: 4994-5004. (PMID: 10528204) [PubMed]

Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 2002; 169: 575-80. (PMID: 12077290) [PubMed]

Greco G, Fruci D, Accapezzato D, Barnaba V, Nisini R, Alimena G, Montefusco E, Vigneti E, Butler R, Tanigaki N, Tosi R. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996; 10: 693-9. (PMID: 8618449) [PubMed]

Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, Ritter G, Wiesneth M, Döhner H, Schmitt M. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005; 106: 938-45. (PMID: 15827130) [PubMed]

Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-17. (PMID: 16931630) [PubMed]

Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 1997; 57: 3238-44. (PMID: 9242455) [PubMed]

Han JF, Zhao TT, Liu HL, Lin ZH, Wang HM, Ruan ZH, Zou LY, Wu YZ. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28. Cancer Immunol Immunother 2006; 55: 1575-83. (PMID: 16534571) [PubMed]

Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 2002; 99: 12275-80. (PMID: 12218171) [PubMed]

Hiltbold EM, Ciborowski P, Finn OJ. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res 1998; 58: 5066-70. (PMID: 9823312) [PubMed]

Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731-9. (PMID: 12060610) [PubMed]

Hogan KT, Coppola MA, Gatlin CL, Thompson LW, Shabanowitz J, Hunt DF, Engelhard VH, Ross MM, Slingluff CL Jr. Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma. Cancer Res 2004; 64:1157-63. (PMID: 14871852) [PubMed]

Huarte E, Sarobe P, Lasarte JJ, Brem G, Weiss EH, Prieto J, Borras-Cuesta F. Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. Int J Cancer 2002; 97: 58-63. (PMID: 11774244) [PubMed]

Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, Ho AD, Goldschmidt H, Klein B, Christensen O. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol 2006; 34: 486-96. (PMID: 16569595) [PubMed]

Ichiki Y, Takenoyama M, Mizukami M, So T, Sugaya M, Yasuda M, Hanagiri T, Sugio K, Yasumoto K. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004; 172: 4844-50. (PMID: 15067062) [PubMed]

Ida K, Kawaguchi S, Sato Y, Tsukahara T, Nabeta Y, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Kamiguchi K, Wada T, Nagoya S, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Ozaki T, Yoshikawa H, Yamashita T, Sato N. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 2004; 173: 1436-43. (PMID: 15240740) [PubMed]

Imai N, Harashima N, Ito M, Miyagi Y, Harada M, Yamada A, Itoh K. Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases. Int J Cancer 2001; 94: 237-42. (PMID: 11668504) [PubMed]

Ito D, Albers A, Zhao YX, Visus C, Appella E, Whiteside TL, DeLeo AB. The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells. J Immunol 2006; 177: 6795-803. (PMID: 17082593) [PubMed]

Ito M, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, Yamada A, Saito N, Itoh K. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 2000; 88: 633-9. (PMID: 11058882) [PubMed]

Jäger D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A, Jäger E. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun [serial online] 2005; 5: 11. URL: http://www.cancerimmunity.org/v5p11/051014.htm (PMID: 16335914) [Abstract]

Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 2006; 103: 14453-8. (PMID: 16984998) [PubMed]

Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004; 88: 29-41. (PMID: 15538043) [PubMed]

Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001; 194: 1313-23. (PMID: 11696596) [PubMed]

Kawahara M, Hori T, Matsubara Y, Okawa K, Uchiyama T. Identification of HLA class I-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis. Exp Hematol 2006; 34: 1496-504. (PMID: 17046569) [PubMed]

Kawano K, Gomi S, Tanaka K, Tsuda N, Kamura T, Itoh K, Yamada A. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res 2000; 60: 3550-8. (PMID: 10910068) [PubMed]

Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 2001; 167: 787-96. (PMID: 11441084) [PubMed]

Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC, Ossendorp F, Melief CJ. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 2006; 20: 1738-50. (PMID: 16932347) [PubMed]

Kierstead LS, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer 2001; 85: 1738-45. (PMID: 11742496) [PubMed]

Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Shichijo S, Yamana H, Itoh K. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 1999; 81: 459-66. (PMID: 10209962) [PubMed]

Kim C, Matsumura M, Saijo K, Ohno T. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 1998; 47: 90-6. (PMID: 9769117) [PubMed]

Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate 2007; 67: 1019-28. (PMID: 17455230) [PubMed]

Knights AJ, Zaniou A, Rees RC, Pawelec G, Müller L. Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 2002; 51: 271-81. (PMID: 12070714) [PubMed]

Kobayashi H, Kokubo T, Takahashi M, Sato K, Miyokawa N, Kimura S, Kinouchi R, Katagiri M. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 1998; 47: 398-403. (PMID: 9510558) [PubMed]

Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000; 60: 5228-36. (PMID: 11016652) [PubMed]

Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006; 55: 850-60. (PMID: 16220325) [PubMed]

Koesters R, Linnebacher M, Coy JF, Germann A, Schwitalle Y, Findeisen P, von Knebel Doeberitz M. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 2004; 109: 385-92. (PMID: 14961577) [PubMed]

Koga M, Shichijo S, Yamada A, Ashihara J, Sawamizu H, Kusukawa J, Itoh K. Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL. Tissue Antigens 2003; 61: 136-45. (PMID: 12694581) [PubMed]

Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998; 78: 202-8. (PMID: 9754653) [PubMed]

Konopitzky R, Konig U, Meyer RG, Sommergruber W, Wolfel T, Schweighoffer T. Identification of HLA-A*0201-restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2. J Immunol 2002; 169: 540-7. (PMID: 12077286) [PubMed]

Kontani K, Teramoto K, Ozaki Y, Fujita T, Tezuka N, Sawai S, Watanabe H, Fujino S, Yokomise H, Ohkubo I. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner. Int J Oncol 2004; 25: 1537-42. (PMID: 15547688) [PubMed]

Krämer BF, Schoor O, Krüger T, Reichle C, Müller M, Weinschenk T, Hennenlotter J, Stenzl A, Rammensee H-G, Stevanovic S. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Ther 2005; 4: 943-8. (PMID: 16082191) [PubMed]

Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K, Schilling M, Pfreundschuh M. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 2006; 12: 1365-72. (PMID: 16489095) [PubMed]

Li B, Wang Y, Chen J, Wu H, Chen W. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin Exp Immunol 2005; 140: 310-9. (PMID: 15807856) [PubMed]

Li G, Hundemer M, Wolfrum S, Ho AD, Goldschmidt H, Witzens-Harig M. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A). Ann Hematol 2006; 85: 583-90. (PMID: 16718496) [PubMed]

Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C, Zeuthen J, Pawelec G. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 1998; 47: 32-8. (PMID: 9755876) [PubMed]

Lotz C, Mutallib SA, Oehlrich N, Liewer U, Ferreira EA, Moos M, Hundemer M, Schneider S, Strand S, Huber C, Goldschmidt H, Theobald M. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL. J Immunol 2005; 175: 1301-9. (PMID: 16002735) [PubMed]

Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002; 62: 5807-12. (PMID: 12384542) [PubMed]

Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005; 65: 6435-42. (PMID: 16024648) [PubMed]

Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer 2005; 115: 333-6. (PMID: 15688394) [PubMed]

Maeda A, Ohguro H, Nabeta Y, Hirohashi Y, Sahara H, Maeda T, Wada Y, Sato T, Yun C, Nishimura Y, Torigoe T, Kuroki Y, Sato N. Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome. Eur J Immunol 2001; 31: 563-72. (PMID: 11180121) [PubMed]

Maia S, Haining WN, Ansén S, Xia Z, Armstrong SA, Seth NP, Ghia P, den Boer ML, Pieters R, Sallan SE, Nadler LM, Cardoso AA. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res 2005; 65: 10050-8. (PMID: 16267031) [PubMed]

Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillère B, Kirkwood JM, Zarour HM. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by Th1-type tumor-reactive CD4+ T cells. Cancer Res 2003; 63: 6506-6515. (PMID: 14559844) [PubMed]

Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007; 30: 274-81. (PMID: 17414318) [PubMed]

May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007; 13: 4547-55. (PMID: 17671141) [PubMed]

Mayr C, Bund D, Schlee M, Bamberger M, Kofler DM, Hallek M, Wendtner C-M. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Exp Hematol 2006; 34: 44-53. (PMID: 16413390) [PubMed]

Meier A, Reker S, Svane IM, Holten-Andersen L, Becker JC, Sondergaard I, Andersen MH, Thor Straten P. Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol Immunother 2005; 54: 219-28. (PMID: 15580499) [PubMed]

Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 2007; 56: 689-98. (PMID: 16937115) [PubMed]

Mitchell MS, Kan-Mitchell J, Minev B, Edman C, Deans RJ. A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes. Cancer Res 2000; 60: 6448-56. (PMID: 11103812) [PubMed]

Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 2006; 118: 1194-204. (PMID: 16152611) [PubMed]

Morel S, Lévy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000; 12: 107-17. (PMID: 10661410) [PubMed]

Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie RF. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol Immunol 1995; 32: 573-81. (PMID: 7541891) [PubMed]

Müller L, Knights A, Pawelec G. Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. Hematol J 2003; 4: 57-66. (PMID: 12692522) [PubMed]

Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 2004; 64: 5481-8. (PMID: 15289358) [PubMed]

Nagata Y, Hanagiri T, Takenoyama M, Fukuyama T, Mizukami M, So T, Ichiki Y, Sugaya M, Sugio K, Yasumoto K. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clin Cancer Res 2005; 11: 5265-72. (PMID: 16033845) [PubMed]

Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000; 164: 2565-74. (PMID: 10679095) [PubMed]

Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002; 32: 826-36. (PMID: 11870627) [PubMed]

Nonaka Y, Tsuda N, Shichijo S, Ito M, Maeda Y, Harada M, Kamura T, Shigemori M, Itoh K. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors. Tissue Antigens 2002; 60: 319-27. (PMID: 12472661) [PubMed]

Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 2000; 109: 616-21. (PMID: 10886212) [PubMed]

Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004; 64: 2610-8. (PMID: 15059918) [PubMed]

Ohkouchi S, Kawamoto N, Koga M, Sakanashi F, Shichijo S, Saijo Y, Nukiwa T, Itoh K, Yamada A. Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. Eur J Immunol 2003; 33: 2964-73. (PMID: 14579264) [PubMed]

Ohminami H, Yasukawa M, Kaneko S, Yakushijin Y, Abe Y, Kasahara Y, Ishida Y, Fujita S. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 1999; 93: 925-35. (PMID: 9920842) [PubMed]

Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product. Immunogenetics 2000; 51: 99-107. (PMID: 10663572) [PubMed]

Okumura H, Noguchi Y, Uenaka A, Aji T, Ono T, Nakagawa K, Aoe M, Shimizu N, Nakayama E. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells. Microbiol Immunol 2005; 49: 1009-16. (PMID: 16301813) [PubMed]

Paschen A, Jing W, Drexler I, Klemm M, Song M, Müller-Berghaus J, Nguyen XD, Osen W, Stevanovic S, Sutter G, Schadendorf D. Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multi-epitope region of melanoma antigen TRP-2. Int J Cancer 2005; 116: 944-8. (PMID: 15856458) [PubMed]

Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AML, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002; 99: 2100-6. (PMID: 11877285) [PubMed]

Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, Kalbacher H. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996; 88: 2118-24. (PMID: 8822931) [PubMed]

Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G, Flyer DC. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003; 15: 751-63. (PMID: 12750359) [PubMed]

Ras E, van der Burg SH, Zegveld ST, Brandt RM, Kuppen PJ, Offringa R, Warnarr SO, van de Velde CJ, Melief CJ. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol 1997; 53: 81-9. (PMID: 9127151) [PubMed]

Redchenko I, Harrop R, Ryan MG, Hawkins RE, Carroll MW. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology 2006; 118: 50-7. (PMID: 16630022) [PubMed]

Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995; 154: 5944-50. (PMID: 7751637) [PubMed]

Rodeberg DA, Nuss RA, Elsawa SF, Erskine CL, Celis E. Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes. Int J Cancer 2006; 119: 126-32. (PMID: 16450380) [PubMed]

Röhn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res 2005; 65: 10068-78. (PMID: 16267033) [PubMed]

Rojas JM, McArdle SEB, Horton RB, Bell M, Mian S, Li G, Ali SA, Rees RC. Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53. Cancer Immunol Immunother 2005; 54: 243-53. (PMID: 15449037) [PubMed]

Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Moller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001; 98: 13255-60. (PMID: 11687624) [PubMed]

Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Karre K, Masucci G, Celis E, Sette A, Southwood S, Appella E, Kiessling R. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res 1997; 57: 4348-55. (PMID: 9331097) [PubMed]

Sasada T, Takedatsu H, Azuma K, Koga M, Maeda Y, Shichijo S, Shoumura H, Hirai T, Takabayashi A, Itoh K. Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res 2004; 64: 2882-8. (PMID: 15087407) [PubMed]

Sato Y, Nabeta Y, Tsukahara T, Hirohashi Y, Syunsui R, Maeda A, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Wada T, Yamashita T, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Umeda T, Ishii S, Kawaguchi S, Sato N. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002; 169: 1611-8. (PMID: 12133991) [PubMed]

Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 2002; 98: 409-14. (PMID: 11920592) [PubMed]

Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 2003; 100: 3398-403. (PMID: 12626761) [PubMed]

Schreurs MW, Kueter EW, Scholten KB, Kramer D, Meijer CJ, Hooijberg E. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Cancer Immunol Immunother 2005 ; 54: 703-12. (PMID: 15726360) [PubMed]

Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res 2003; 9: 3260-71. (PMID: 12960111) [PubMed]

Sharkey MS, Lizée G, Gonzales MI, Patel S, Topalian SL. CD4+ T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004; 64: 1595-9. (PMID: 14996715) [PubMed]

Sharma P, Gnjatic S, Jungbluth AA, Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE, Santiago D, Chen YT, Bajorin DF, Ritter G, Old LJ. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun [serial online] 2003; 3: 19. URL: http://www.cancerimmunity.org/v3p19/031119.htm (PMID: 14680360) [Abstract]

Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187: 277-88. (PMID: 9449708) [PubMed]

Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, Ishihara Y, Itoh K. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Clin Cancer Res 2004; 10: 5828-36. (PMID: 15355913) [PubMed]

Smyth LJ, Elkord E, Taher TE, Jiang HR, Burt DJ, Clayton A, van Veelen PA, de Ru A, Ossendorp F, Melief CJ, Drijfhout JW, Dermime S, Hawkins RE, Stern PL. Cd8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer 2006; 119: 1638-147. (PMID: 16646078) [PubMed]

So T, Takenoyama M, Mizukami M, Ichiki Y, Sugaya M, Hanagiri T, Sugio K, Yasumoto K. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005; 65: 5945-52. (PMID: 15994973) [PubMed]

Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006; 66: 3287-93. (PMID: 16540682) [PubMed]

Sommerfeldt N, Beckhove P, Ge Y, Schütz F, Choi C, Bucur M, Domschke C, Sohn C, Schneeweis A, Rom J, Pollmann D, Leucht D, Vlodavsky I, Schirrmacher V. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 2006; 66: 7716-23. (PMID: 16885374) [PubMed]

Sun Y, Song M, Stevanovic S, Jankowiak C, Paschen A, Rammensee HG, Schadendorf D. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer 2000; 87: 399-404. (PMID: 10897046) [PubMed]

Sun Y, Stevanovic S, Song M, Schwantes A, Kirkpatrick CJ, Schadendorf D, Cichutek K. The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Blood 2006; 107: 1476-83. (PMID: 16234362) [PubMed]

Suzuki K, Sahara H, Okada Y, Yasoshima T, Hirohashi Y, Nabeta Y, Hirai I, Torigoe T, Takahashi S, Matsuura A, Takahashi N, Sasaki A, Suzuki M, Hamuro J, Ikeda H, Wada Y, Hirata K, Kikuchi K, Sato N. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. J Immunol 1999; 163: 2783-91. (PMID: 10453022) [PubMed]

Tamura M, Nishizaka S, Maeda Y, Ito M, Harashima N, Harada M, Shichijo S, Itoh K. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes. Jpn J Cancer Res 2001; 92: 762-7. (PMID: 11473727) [PubMed]

Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997; 57: 4465-8. (PMID: 9377553) [PubMed]

Tanaka Y, Takahashi T, Nieda M, Masuda S, Kashiwase K, Ogawa S, Chiba S, Juji T, Hirai H. Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes. Br J Haematol 2000; 109: 435-7. (PMID: 10848838) [PubMed]

Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003; 9: 947-54. (PMID: 12631591) [PubMed]

Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003; 63: 4481-9. (PMID: 12907621) [PubMed]

ten Bosch GJ, Kessler JH, Joosten AM, Bres-Vloemans AA, Geluk A, Godthelp BC, van Bergen J, Melief CJ, Leeksma OC. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood 1999; 94: 1038-45. (PMID: 10419896) [PubMed]

ten Bosch GJA, Toornvliet AC, Friede T, Melief CJM, Leeksma OC. Recognition of peptides corresponding to the joining region of p210 ^BCR-ABL protein by human T cells. Leukemia 1995; 9: 1344-8. (PMID: 7643623) [PubMed]

Touloukian CE, Leitner WW, Robbins PF, Rosenberg SA, Restifo NP. Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen. Cancer Res 2001; 61: 8100-4. (PMID: 11719435) [PubMed]

Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 2001; 61: 4761-5. (PMID: 11406549) [PubMed]

Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51: 614-20. (PMID: 12439606) [PubMed]

Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001; 84: 1052-7. (PMID: 11308253) [PubMed]

van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res 2006; 66: 1818-23. (PMID: 16452243) [PubMed]

Visseren MJ, van der Burg SH, van der Voort EI, Brandt RM, Schrier PI, van der Bruggen P, Boon T, Melief CJ, Kast WM. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 1997; 73: 125-30. (PMID: 9334819) [PubMed]

Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Cancer Res 2007; 67: 5300-7. (PMID: 17545610) [PubMed]

Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001; 7: 3343-8. (PMID: 11705846) [PubMed]

Voo KS, Zeng G, Mu JB, Zhou J, Su XZ, Wang RF. CD4+ T-cell response to mitochondrial cytochrome B in human melanoma. Cancer Res 2006; 66: 5919-26. (PMID: 16740732) [PubMed]

Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. Cancer Immun [serial online] 2003; 3: 18. URL: http://www.cancerimmunity.org/v3p18/031117.htm (PMID: 14677925) [Abstract]

Wagner WM, Ouyang Q, Pawelec G. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes. Cancer Immunol Immunother 2003; 52: 89-96. (PMID: 12594572) [PubMed]

Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanovic S, Rammensee HG. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002; 62: 5818-27. (PMID: 12384544) [PubMed]

Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK, Chen W, Low WC. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 2006; 76: 23-30. (PMID: 16155724) [PubMed]

Würtzen PA, Claesson MH. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer 2002; 99: 568-72. (PMID: 11992547) [PubMed]

Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001; 61: 6459-66. (PMID: 11522641) [PubMed]

Yamada A, Kawano K, Koga M, Takamori S, Nakagawa M, Itoh K. Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes. Cancer Res 2003; 63: 2829-35. (PMID: 12782588) [PubMed]

Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin Cancer Res 2004; 10: 890-6. (PMID: 14871964) [PubMed]

Yan Y, Chen Y, Yang F, Chen IH, Xiong Z, Wang J, Lachman LB, Wang H, Yang XF. HLA-A2.1-restricted T cells react to SEREX-defined tumor antigen CML66L and are suppressed by CD4+CD25+ regulatory T cells. Int J Immunopathol Pharmacol 2007; 20: 75-89. (PMID: 17346430) [PubMed]

Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 4056-63. (PMID: 10463607) [PubMed]

Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao S, Kishi K, Kubonishi I, Dan K, Fujita S. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1998; 92: 3355-61. (PMID: 9787173) [PubMed]

Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 2005; 11: 6342-51. (PMID: 16144939) [PubMed]

Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170: 5391-7. (PMID: 12759413) [PubMed]

Zhu B, Chen Z, Cheng X, Lin Z, Guo J, Jia Z, Zou L, Wang Z, Hu Y, Wang D, Wu Y. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin Cancer Res 2003; 9: 1850-7. (PMID: 12738743) [PubMed]